Alternative therapy and abnormal liver function during adjuvant chemotherapy in breast cancer patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ahn, J.H. | - |
dc.contributor.author | Kim, S.B. | - |
dc.contributor.author | Yun, M.R. | - |
dc.contributor.author | Lee, J.S. | - |
dc.contributor.author | Kang, Y.K. | - |
dc.contributor.author | Kim, W.K. | - |
dc.date.accessioned | 2022-04-11T07:40:29Z | - |
dc.date.available | 2022-04-11T07:40:29Z | - |
dc.date.issued | 2004-06 | - |
dc.identifier.issn | 1011-8934 | - |
dc.identifier.issn | 1598-6357 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/56107 | - |
dc.description.abstract | Although hepatotoxicity has been rarely reported during adjuvant chemotherapy in breast cancer patients,we observed a high frequency in our patients who were also taking alternative agents. We therefore sought to determine the association between hepatotoxicity and alternative agents during adjuvant chemotherapy in breast cancer patients. All breast cancer patients were treated with the same chemotherapeutic regimen and had normal baseline liver function test (LFT). LFT was checked repeatedly during each cycle of chemotherapy. Patients showing LIFT abnormalities were asked about use of alternative agents, and, after the end of chemotherapy, a questionnaire was administered to each patient on their use of alternative agents. Of 178 patients, 65 (36.5%) admitted using alternative therapy, and significantly more patients in this group developed LFT abnormalities (37/65, 56.9%) than those who denied taking alternative therapy (25/113, 22.1%, p=0.001). Although LFT abnormalities were mild to moderate and normalized in most patients after cessation of alternative agents, it remained a serious problem in one patient. In conclusion, alternative therapy may be one of the etiologies for abnormal LIFT in breast cancer patients receiving adjuvant chemotherapy. | - |
dc.format.extent | 4 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | KOREAN ACAD MEDICAL SCIENCES | - |
dc.title | Alternative therapy and abnormal liver function during adjuvant chemotherapy in breast cancer patients | - |
dc.type | Article | - |
dc.identifier.doi | 10.3346/jkms.2004.19.3.397 | - |
dc.identifier.bibliographicCitation | JOURNAL OF KOREAN MEDICAL SCIENCE, v.19, no.3, pp 397 - 400 | - |
dc.identifier.kciid | ART000954662 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000222373300013 | - |
dc.identifier.scopusid | 2-s2.0-3042708806 | - |
dc.citation.endPage | 400 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 397 | - |
dc.citation.title | JOURNAL OF KOREAN MEDICAL SCIENCE | - |
dc.citation.volume | 19 | - |
dc.type.docType | Article | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | breast neoplasms | - |
dc.subject.keywordAuthor | complementary therapies | - |
dc.subject.keywordAuthor | drug therapy | - |
dc.subject.keywordAuthor | hepatitis | - |
dc.subject.keywordAuthor | toxic | - |
dc.subject.keywordPlus | NON-HODGKINS-LYMPHOMA | - |
dc.subject.keywordPlus | COMPLEMENTARY/ALTERNATIVE MEDICINE | - |
dc.subject.keywordPlus | HEPATIC TOXICITY | - |
dc.subject.keywordPlus | LAMIVUDINE | - |
dc.subject.keywordPlus | WOMEN | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.